RDA 9th Plenary Joint meeting: WG BioSharing Registry, IG ELIXIR Bridging Force

You are here

10 January 2017 2582 reads

Meeting title

What's happened in the Life Sciences

Groups: WG BioSharing Registry: connecting data policies, standards & databases in life sciences, IG ELIXIR Bridging Force

Co-Chairs: Susanna-Assunta Sansone; Rob Hooft; Bengt Persson; Niclas Jareborg; Peter McQuilton

Short introduction describing the activities and the scope of the groups: 

ELIXIR is the European inter-governmental organization of 20 member nodes, including EMBL-EBI, in 19 countries (https://www.elixir-europe.org), representing the European bioinformatics capacity and key research infrastructure resources. Operating in the life, environmental and biomedical sciences, ELIXIR works closely with the USA National Institutes of Health (NIH), Big Data to Knowledge Initiative (BD2K) and other EU infrastructure programmes (also represented in the RDA GEDE group). The ELIXIR Bridging Force Interest Group, as its name suggests, serves as a bridge between ELIXIR and relevant RDA Interest Groups, e.g. those on agricultural data, big data analysis, federated identity management, marine data, structural biology, toxicogenomics, and data publishing. The ELIXIR Bridging Force IG works as an information bridge between RDA and ELIXIR and other relevant organisations. 

BioSharing (https://biosharing.org) is a curated, informative and educational resource on inter-related data standards, databases, and policies in the life, environmental and biomedical sciences, part of the ELIXIR Interoperability Platform. The BioSharing WG, which started in September 2015, has worked on principles to link information on databases, content standards and journal and funder policies in the life sciences, leveraging the existing BioSharing portal (https://www.biosharing.org). This use cases-driven WG is a joint effort with Force11 and is led and constituted by prospective adopters as well as technical implementers, many of whom are also leading and/or actively involved in other relevant RDA IGs and WGs.

Additional links to informative material related to the group i.e. group page, Case statement, working documents etc

ELIXIR Bridging Force IG - https://www.rd-alliance.org/groups/elixir-bridging-force-ig.html

BioSharing WG - https://rd-alliance.org/group/biosharing-registry-connecting-data-polici...
BioSharing case statement - https://rd-alliance.org/group/biosharing-registry-connecting-data-polici...
BioSharing 2016 plenary output presentation - http://www.tvworldwide.com/events/idw/161117/default.cfm?id=16703&type=f...

Meeting objectives

In this session we will discuss how ELIXIR is working on the implementation of the FAIR principles and assisting life scientists to provide increasing levels of FAIRness to their data. We will showcase and discuss the preliminary output of the BioSharing WG, set to educate and inform researchers, standard/database developers, funders, journal editors, librarians and data managers to understand which standards and databases are mature and appropriate to their use case. This joint session will summarize key and core work happening in the ELIXIR Nodes and Platforms (Data, Compute, Interoperability, Tools and Training) to enable a bidirectional dissemination and interaction with the RDA. 

Meeting agenda

11:30 - 11:45 Introduction to the session (Mikael Borg, ELIXIR-Sweden)
11:45 - 12:05 Progress in the ELIXIR interoperability platform (Rob Hooft, ELIXIR-NL)
12:05 - 12:25 Adoption of BioSharing - 20 mins on BioSharing, RDA outputs and links to ELIXIR (Peter McQuilton, BioSharing/ELIXIR-UK)
12:25 - 12:40 Progress on Data Management Planning in the ELIXIR Training platform: portal and identified training needs. (Rob Hooft, ELIXIR-NL)
12:40-13:00 Update on collaborations between BD2K and ELIXIR (Ian Fore, NIH).


All members of the RDA. Particularly those with an interest in the FAIR principles, data standards and data policy. The work presented in this sessions can also be translated to other domains.

Group chairs serving as contacts: Peter McQuilton

Type of meeting: Informative meeting